Q3 2024 Mirum Pharmaceuticals Inc Earnings Call Transcript

Nov 12, 2024 / 01:30PM GMT

Release Date Price: $42.28 (+1.61%)

Transcript 10-Q8-K

Key Points

Positve

Mirum Pharmaceuticals Inc (MIRM) reported a significant increase in net product sales, reaching $90.3 million in Q3 2024, an 89% increase from the same quarter last year.
The company has raised its full-year 2024 guidance to $330 to $335 million in net product revenue, reflecting strong commercial execution.
Mirum Pharmaceuticals Inc (MIRM) received breakthrough therapy designation for its drug candidate in treating cholestatic pruritus in PBC, highlighting its potential effectiveness.
The company achieved positive operating cash flow for the first time in Q3 2024, indicating improved financial health.
Mirum Pharmaceuticals Inc (MIRM) expanded its pipeline with the addition of MRM 3,379, a candidate for treating Fragile X syndrome, aligning with its strategy in rare genetic neurology.

Negative

Despite strong sales growth, Mirum Pharmaceuticals Inc (MIRM) reported a net loss of $15 million for Q3 2024.
The company's total operating expenses were high at $103.9 million, which includes significant R&D and SG&A expenses.
Mirum Pharmaceuticals Inc (MIRM) faces challenges in pricing and reimbursement negotiations in Europe for its products.
The company has a substantial milestone payment obligation, including a $10 million payment to Takeda and future payments related to MRM 3,379.
There is uncertainty regarding the regulatory path and endpoints for the newly acquired Fragile X syndrome program, which may impact future development timelines.

Operator

Hello, everyone and welcome to the Mirum Pharmaceuticals third quarter, 2024 financial results and business update. My name is Seb and I'll be the operator for your call today. If you would like to ask a question during the Q&A session, please press star one on your telephone keypad. If you would like to withdraw your question, please press star two.

I will now hand you over to Andrew mckibbin, Vice President of Investor Relations and Finance. Please go ahead.

Andrew Mckibben

Mirum Pharmaceuticals Inc - IR Contact Officer

Thanks, Seb and Good morning, everyone. I'd like to welcome you to my pharmaceuticals' third quarter, 2024 conference call. I'm joined today by our CEO Chris Peetz, our President and Chief Operating Officer, Peter Radovich, our Chief Medical Officer, Joanne Kwan and Eric Beols, our Chief Financial Officer earlier today, Miriem issued a news release announcing the company's results for the third quarter, 2024 copies of this news release and sec filings can be found in the investors section of our website before we start. I'd like

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.